ORAI2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2399069	0.54	7/20
Diphenyl Borinic Acid (SCHEMBL40601)	1.00	6/20
SCHEMBL2412647	0.93	6/20
SCHEMBL2406379	0.82	6/20
SCHEMBL2406124	0.78	6/20
SCHEMBL2405808	0.72	6/20
SCHEMBL1138231	0.70	6/20
SCHEMBL2411541	0.64	6/20
SCHEMBL2408532	0.62	6/20
SCHEMBL2408066	0.56	6/20
SCHEMBL1003006	1.00	5/20
SCHEMBL2964428	1.00	5/20
SCHEMBL1138482	0.80	5/20
SCHEMBL2407457	0.74	5/20
SCHEMBL2400633	0.58	5/20
SCHEMBL2398673	0.54	5/20
SCHEMBL974659	0.52	5/20
SCHEMBL2405727	0.46	5/20
Toluene (SCHEMBL735933)	0.41	5/20
SCHEMBL2406706	1.00	4/20

Clinical trials — most relevant to ORAI2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1	PHASE4	COMPLETED
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination	PHASE4	UNKNOWN
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
The Re-Prosper HF Study	PHASE2/PHASE3	COMPLETED
Can Calcium Ionophore Application Enhance the ICSI Outcomes in Severe Male Factor Infertility?	PHASE2/PHASE3	UNKNOWN
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.	PHASE2	NOT_YET_RECRUITING
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Calcium Channel Blockade in Primary Aldosteronism	PHASE2	COMPLETED
Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction	PHASE2	ACTIVE_NOT_RECRUITING
Lovaza's Effect on the Activation of Platelets	PHASE2	COMPLETED
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain	PHASE2	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Effects of Photobiomodulation on the Innate Immune System of Neonates and Infants With Bronchiolitis	nan	UNKNOWN
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)	nan	COMPLETED
Comparison of Two Types of Calcium (Ca²⁺) Ionophore Treatments for Oocyte Activation in Cases of Suboptimal Fertilization Potential	nan	NOT_YET_RECRUITING
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants	nan	RECRUITING
Piezo2-related Arthrogryposis & physiopathOLOgy 3	nan	NOT_YET_RECRUITING
Microneurographic Assessment of Peripheral Nerves in Healthy Volunteers and Individuals With Sensory Dysfunction Caused by Inherited Mutations in the PIEZO2 Gene	nan	RECRUITING
Calcium Handling and Epicardial Ablation	nan	COMPLETED
Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines	nan	UNKNOWN
Preliminary Study for Identification of Calcium-Binding Proteins in the Serum in Various Metabolic Bone Disorders	nan	UNKNOWN
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure	nan	UNKNOWN
Biometric and Biological Data for Diagnosis and Therapy of Pain Patients	nan	UNKNOWN
How Secreted-embryo-derived Trypsin Initiates, Maintains and Terminates Ca2+ Signals in Uterine Epithelial Cells	nan	COMPLETED
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism	nan	UNKNOWN
Feasibility of Improving Risk Stratification in Brugada Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ORAI2 binder may also engage these)

Protein	Name	Similarity
Q8BH10	—	1.000	Q8BH10 →
Q5ZLW2	—	1.000	Q5ZLW2 →
Q6NZI6	—	0.997	Q6NZI6 →
Q6P8G8	—	0.993	Q6P8G8 →
Q6AXR8	—	0.985	Q6AXR8 →
ORAI3	Protein orai-3 (Transmembrane protein 142C)	0.984	landscape →
Q8BWG9	—	0.983	Q8BWG9 →
ORAI1	Calcium release-activated calcium channel protein 1	0.980	landscape →
Q5M848	—	0.978	Q5M848 →
Q5EAU0	—	0.974	Q5EAU0 →
Q3UDR8	—	0.968	Q3UDR8 →
Q8BUV8	—	0.968	Q8BUV8 →
Q09232	—	0.966	Q09232 →
D3ZWZ9	—	0.966	D3ZWZ9 →
Q5ZKN3	—	0.965	Q5ZKN3 →
Q9GZM5	—	0.965	Q9GZM5 →
Q8CB19	—	0.965	Q8CB19 →
Q7ZYA0	—	0.965	Q7ZYA0 →
Q6P4P2	—	0.964	Q6P4P2 →
Q5VW38	—	0.964	Q5VW38 →
Q5F384	—	0.964	Q5F384 →
Q9QZ09	—	0.963	Q9QZ09 →
Q8BKU8	—	0.963	Q8BKU8 →
Q94CA0	—	0.963	Q94CA0 →
Q61542	—	0.963	Q61542 →
Q9NXL6	—	0.963	Q9NXL6 →
X1WEM4	—	0.963	X1WEM4 →
Q96MT1	—	0.963	Q96MT1 →
Q6TUD4	—	0.963	Q6TUD4 →
Q5SWK7	—	0.962	Q5SWK7 →